Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
{{output}}
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of ... ...
